Literature DB >> 24729396

Regulatory B cells are numerically but not functionally deficient in anti-neutrophil cytoplasm antibody-associated vasculitis.

Sarah Katrina Todd1, Ruth J Pepper1, Juliana Draibe1, Anisha Tanna1, Charles D Pusey1, Claudia Mauri1, Alan D Salama2.   

Abstract

OBJECTIVES: B cells are central to the pathology of ANCA-associated vasculitis (AAV), a disease characterized by autoantibodies and effectively treated by rituximab. In addition to promoting inflammation, a subset of B cells act to suppress harmful autoimmune responses (Breg). The balance of effector and regulatory B cell subsets in AAV is not known. This study was conducted to assess the relative frequency of these subsets during different states of disease activity.
METHODS: B memory (Bmem), naive (Bnaive) and regulatory (Breg) subsets were defined by their relative expression of CD24 and CD38. Function was assessed by cytokine production and suppressive action on CD4(+) Th1 activation evaluated in a co-culture system.
RESULTS: Compared with healthy controls, the frequency of Breg (CD24(hi)CD38(hi)) was significantly reduced during disease remission in both proteinase 3 (PR3)- and MPO-ANCA patients and during acute disease in PR3-ANCA patients, while the frequency of memory cells (CD24(hi)CD38(lo)) was reduced during active disease and restored during remission. Breg cell frequency showed a positive correlation, while Bmem had an inverse correlation with IL-10 production in vitro. B and T cell co-cultures revealed that memory and naive B cell subsets augmented Th1 activation in vitro, which was prevented by Breg, and this pattern did not differ between remission AAV patients and controls.
CONCLUSION: In remission there is a numerical, but not functional, deficiency in Breg and preservation of Bmem associated with reduced IL-10 production and increased Th1 activation in vitro. This imbalance may contribute to the high rate of relapse observed in AAV, especially in PR3-ANCA patients.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  ANCA-associated vasculitis; B lymphocyte subsets; B regulatory cells

Mesh:

Substances:

Year:  2014        PMID: 24729396      PMCID: PMC4135583          DOI: 10.1093/rheumatology/keu136

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  37 in total

Review 1.  B cells as antigen presenting cells.

Authors:  Daniel Rodríguez-Pinto
Journal:  Cell Immunol       Date:  2006-03-30       Impact factor: 4.868

Review 2.  Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies.

Authors:  J Charles Jennette; Hong Xiao; Ronald J Falk
Journal:  J Am Soc Nephrol       Date:  2006-04-19       Impact factor: 10.121

Review 3.  Phenotypic and functional heterogeneity of human memory B cells.

Authors:  Iñaki Sanz; Chungwen Wei; F Eun-Hyung Lee; Jennifer Anolik
Journal:  Semin Immunol       Date:  2008-02-06       Impact factor: 11.130

4.  Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies.

Authors:  C Prussin; D D Metcalfe
Journal:  J Immunol Methods       Date:  1995-12-15       Impact factor: 2.303

5.  Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells.

Authors:  Aharon Kessel; Tharwat Haj; Regina Peri; Ayelet Snir; Doron Melamed; Edmond Sabo; Elias Toubi
Journal:  Autoimmun Rev       Date:  2011-12-02       Impact factor: 9.754

6.  Expansion of functionally immature transitional B cells is associated with human-immunodeficient states characterized by impaired humoral immunity.

Authors:  Amanda K Cuss; Danielle T Avery; Jennifer L Cannons; Li Jun Yu; Kim E Nichols; Peter J Shaw; Stuart G Tangye
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

7.  IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro.

Authors:  Jean-David Bouaziz; Sebastien Calbo; Maud Maho-Vaillant; Anne Saussine; Martine Bagot; Armand Bensussan; Philippe Musette
Journal:  Eur J Immunol       Date:  2010-10       Impact factor: 5.532

8.  The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals.

Authors:  Koichi Yanaba; Jean-David Bouaziz; Takashi Matsushita; Takeshi Tsubata; Thomas F Tedder
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

9.  CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients.

Authors:  Paul A Blair; Lina Yassin Noreña; Fabian Flores-Borja; David J Rawlings; David A Isenberg; Michael R Ehrenstein; Claudia Mauri
Journal:  Immunity       Date:  2010-01-14       Impact factor: 31.745

10.  Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions.

Authors:  Ayumi Yoshizaki; Tomomitsu Miyagaki; David J DiLillo; Takashi Matsushita; Mayuka Horikawa; Evgueni I Kountikov; Rosanne Spolski; Jonathan C Poe; Warren J Leonard; Thomas F Tedder
Journal:  Nature       Date:  2012-10-14       Impact factor: 49.962

View more
  25 in total

Review 1.  B Cells, Antibodies, and More.

Authors:  William Hoffman; Fadi G Lakkis; Geetha Chalasani
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-23       Impact factor: 8.237

2.  Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Sebastian Unizony; Noha Lim; Deborah J Phippard; Vincent J Carey; Eli M Miloslavsky; Nadia K Tchao; David Iklé; Adam L Asare; Peter A Merkel; Paul A Monach; Philip Seo; E William St Clair; Carol A Langford; Robert Spiera; Gary S Hoffman; Cees G M Kallenberg; Ulrich Specks; John H Stone
Journal:  Arthritis Rheumatol       Date:  2015-02       Impact factor: 10.995

3.  Circulating regulatory B cell subsets in patients with neuromyelitis optica spectrum disorders.

Authors:  Jinming Han; Li Sun; Zhongkun Wang; Xueli Fan; Lifang Wang; Yang-Yang Song; Jie Zhu; Tao Jin
Journal:  Neurol Sci       Date:  2017-04-07       Impact factor: 3.307

Review 4.  Could Lymphocyte Profiling be Useful to Diagnose Systemic Autoimmune Diseases?

Authors:  Guillermo Carvajal Alegria; Pierre Gazeau; Sophie Hillion; Claire I Daïen; Divi Y K Cornec
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

5.  The Regulatory B Cell Compartment Expands Transiently During Childhood and Is Contracted in Children With Autoimmunity.

Authors:  Ioannis Kalampokis; Guglielmo M Venturi; Jonathan C Poe; Jeffrey A Dvergsten; John W Sleasman; Thomas F Tedder
Journal:  Arthritis Rheumatol       Date:  2017-01       Impact factor: 10.995

Review 6.  Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives.

Authors:  Eva Schrezenmeier; David Jayne; Thomas Dörner
Journal:  J Am Soc Nephrol       Date:  2018-01-11       Impact factor: 10.121

7.  Reduced CD5(+) CD24(hi) CD38(hi) and interleukin-10(+) regulatory B cells in active anti-neutrophil cytoplasmic autoantibody-associated vasculitis permit increased circulating autoantibodies.

Authors:  L T Aybar; J G McGregor; S L Hogan; Y Hu; C E Mendoza; E J Brant; C J Poulton; C D Henderson; R J Falk; D O Bunch
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

Review 8.  Update on ANCA-associated vasculitis: from biomarkers to therapy.

Authors:  Martina Tedesco; Maurizio Gallieni; Francesca Pellegata; Mario Cozzolino; Federico Alberici
Journal:  J Nephrol       Date:  2019-07-12       Impact factor: 3.902

Review 9.  FoxP3 Expression in Macrophages, Cancer, and B Cells-Is It Real?

Authors:  Zahava Vadasz; Elias Toubi
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667

Review 10.  The Role of Regulatory B cells in Kidney Diseases.

Authors:  Wang Long; Hedong Zhang; Wenjia Yuan; Gongbin Lan; Zhi Lin; Longkai Peng; Helong Dai
Journal:  Front Immunol       Date:  2021-05-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.